Phytomedicine nanoformulations for Parkinson's disease

Background: Current medications for Parkinson's disease (PD) primarily offer symptomatic relief, and often lead to adverse effects on long-term use. This highlights the need for disease-modifying therapies. In recent years, attentions of both clinicians and patients have shifted to herbal medic...

Full description

Saved in:
Bibliographic Details
Main Authors: Chinthu V. Saji, K P Mohanakumar, Rajesh A Shenoi
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:Phytomedicine Plus
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2667031324001787
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823861195579326464
author Chinthu V. Saji
K P Mohanakumar
Rajesh A Shenoi
author_facet Chinthu V. Saji
K P Mohanakumar
Rajesh A Shenoi
author_sort Chinthu V. Saji
collection DOAJ
description Background: Current medications for Parkinson's disease (PD) primarily offer symptomatic relief, and often lead to adverse effects on long-term use. This highlights the need for disease-modifying therapies. In recent years, attentions of both clinicians and patients have shifted to herbal medicines that are rich source of bioactive compounds with therapeutic potential to target multiple pathways involved in PD pathology. When integrated with nanotechnology, phytomedicines can overcome key limitations of herbal molecules, such as poor solubility, low bioavailability, and difficulty in crossing the blood brain barrier (BBB). Methods: A literature survey was conducted using PubMed. Studies were categorized into in vitro and in vivo models of the disease for assessing their relevance and impact on PD research. Results: The review identified 26 nanoformulations from seven distinct herbal molecules and eight different whole plant extracts that have been evaluated for their effectiveness in treating PD and other brain disorders. In vitro studies demonstrated enhanced cellular uptake and neuroprotective effects, while in vivo models showed improved pharmacokinetics, BBB permeability and neuroprotective outcomes. Additionally, nine plant-derived compounds with potential effects against PD, but are not nanoformulated were investigated, highlighting their neuroprotective mechanisms but exposing the existing limitations. This article emphasizes the improved neuroprotective effects of nanoformulated herbal compounds in cellular and animal models of PD and outlines the mechanisms by which these nanoformulations enhance BBB penetration. Conclusions: Phytomedicines formulated using nanoliposomes, nanoemlusions, polymeric nanoparticles, nanocrystals and metal nanoparticles have shown promise in improving the drug bioavailability and BBB penetration, resulting in better therapeutic effect in PD cellular and animal models. However, challenges such as scalability, regulatory compliance, and concerns over long term safety of these nanoformulations have to be considered for them to be clinically viable. Hence addressing these issues through rigorous preclinical and clinical testing is essential to confirm their safety and therapeutic potential. Further advancements in PD treatment could be achieved by developing multicomponent herbal nanoformulations that act synergistically on multiple PD targets. This approach may be effective in addressing the underlying pathogenesis of PD, thereby slowing the disease progression.
format Article
id doaj-art-92de28aa3a5f422e890dae26131c8229
institution Kabale University
issn 2667-0313
language English
publishDate 2025-02-01
publisher Elsevier
record_format Article
series Phytomedicine Plus
spelling doaj-art-92de28aa3a5f422e890dae26131c82292025-02-10T04:35:12ZengElsevierPhytomedicine Plus2667-03132025-02-0151100704Phytomedicine nanoformulations for Parkinson's diseaseChinthu V. Saji0K P Mohanakumar1Rajesh A Shenoi2Inter University Centre for Biomedical Research and Super Speciality Hospital, Mahatma Gandhi University Campus at Thalappady, Rubber Board PO, Kottayam, Kerala 686009, IndiaInter University Centre for Biomedical Research and Super Speciality Hospital, Mahatma Gandhi University Campus at Thalappady, Rubber Board PO, Kottayam, Kerala 686009, IndiaCorresponding author.; Inter University Centre for Biomedical Research and Super Speciality Hospital, Mahatma Gandhi University Campus at Thalappady, Rubber Board PO, Kottayam, Kerala 686009, IndiaBackground: Current medications for Parkinson's disease (PD) primarily offer symptomatic relief, and often lead to adverse effects on long-term use. This highlights the need for disease-modifying therapies. In recent years, attentions of both clinicians and patients have shifted to herbal medicines that are rich source of bioactive compounds with therapeutic potential to target multiple pathways involved in PD pathology. When integrated with nanotechnology, phytomedicines can overcome key limitations of herbal molecules, such as poor solubility, low bioavailability, and difficulty in crossing the blood brain barrier (BBB). Methods: A literature survey was conducted using PubMed. Studies were categorized into in vitro and in vivo models of the disease for assessing their relevance and impact on PD research. Results: The review identified 26 nanoformulations from seven distinct herbal molecules and eight different whole plant extracts that have been evaluated for their effectiveness in treating PD and other brain disorders. In vitro studies demonstrated enhanced cellular uptake and neuroprotective effects, while in vivo models showed improved pharmacokinetics, BBB permeability and neuroprotective outcomes. Additionally, nine plant-derived compounds with potential effects against PD, but are not nanoformulated were investigated, highlighting their neuroprotective mechanisms but exposing the existing limitations. This article emphasizes the improved neuroprotective effects of nanoformulated herbal compounds in cellular and animal models of PD and outlines the mechanisms by which these nanoformulations enhance BBB penetration. Conclusions: Phytomedicines formulated using nanoliposomes, nanoemlusions, polymeric nanoparticles, nanocrystals and metal nanoparticles have shown promise in improving the drug bioavailability and BBB penetration, resulting in better therapeutic effect in PD cellular and animal models. However, challenges such as scalability, regulatory compliance, and concerns over long term safety of these nanoformulations have to be considered for them to be clinically viable. Hence addressing these issues through rigorous preclinical and clinical testing is essential to confirm their safety and therapeutic potential. Further advancements in PD treatment could be achieved by developing multicomponent herbal nanoformulations that act synergistically on multiple PD targets. This approach may be effective in addressing the underlying pathogenesis of PD, thereby slowing the disease progression.http://www.sciencedirect.com/science/article/pii/S2667031324001787Herbal moleculesHerbal extractsBlood brain barrier permeabilityLiposomesNanoemulsionsNanocomposites
spellingShingle Chinthu V. Saji
K P Mohanakumar
Rajesh A Shenoi
Phytomedicine nanoformulations for Parkinson's disease
Phytomedicine Plus
Herbal molecules
Herbal extracts
Blood brain barrier permeability
Liposomes
Nanoemulsions
Nanocomposites
title Phytomedicine nanoformulations for Parkinson's disease
title_full Phytomedicine nanoformulations for Parkinson's disease
title_fullStr Phytomedicine nanoformulations for Parkinson's disease
title_full_unstemmed Phytomedicine nanoformulations for Parkinson's disease
title_short Phytomedicine nanoformulations for Parkinson's disease
title_sort phytomedicine nanoformulations for parkinson s disease
topic Herbal molecules
Herbal extracts
Blood brain barrier permeability
Liposomes
Nanoemulsions
Nanocomposites
url http://www.sciencedirect.com/science/article/pii/S2667031324001787
work_keys_str_mv AT chinthuvsaji phytomedicinenanoformulationsforparkinsonsdisease
AT kpmohanakumar phytomedicinenanoformulationsforparkinsonsdisease
AT rajeshashenoi phytomedicinenanoformulationsforparkinsonsdisease